Talk:Spironolactone

message: As far as I know, spironolactone also has anti-androgenic affect as an adverse effect. can anyone vertify this for me?
:There is absolutely no need to doubt this.  Spironolactone is a commonly perscribed anti-androgen for transexual MTFs.  It's one of the safest anti-androgens to use, and antagonizes both the production of androgens and their ability to react with the body.  The adverse effects listed "gynecomastia", "testicular atrophy", and "impotence" are all results of the anti-androgen effects of spironolactone.  As it is an anti-androgen, I would also presume that it also reversibly decreases fertility. --Puellanivis 19:50, 2 October 2006 (UTC)
replies: text: While I take Estradiol sublingually, I still swallow my Spironolactone tablets.  I have heard that it's probably not a good idea to take Spiro sublingually.  Most people find the taste very unpleasant and taking it sublingually could result in systemic toxicity.  Andrea Parton (talk) 10:12, 12 April 2008 (UTC)
replies: text: To add to this, from what I understand there's not really any negative first-pass effect from spironolactone like there is with oral forms of estradiol.  The pills are most effective when absorbed through the gastrointestinal tract, plus you can avoid that incredibly horrible taste!75.76.6.97 (talk) 05:24, 28 April 2009 (UTC)
thread_title: Heading

message: the table on the right shows the half-life for spironolactone as 10 minutes.  the pharmacokinetic paragraph states the half-life is 85 minutes.  Please leave feedback to this issue, as it would be much appreciated.
206.18.168.16 (talk) 14:28, 19 June 2008 (UTC)
thread_title:  inconsistency in half-life estimations (parent compound) 

message: I am not sure about the value of the statement regarding American diets and spiro. As it correctly states, no doctor would suggest using it in the absence of pathology. Using potassium sparing diuretics without follow up blood tests is dangerous as hyperkalaemia-induced cardiac arrythmias could result and hyponatraemia could also be induced. This sentence, in my opinion, makes people think of using spiro inappropriately and does not add to the otherwise strong content. 92.28.134.167 (talk) 21:02, 14 July 2009 (UTC)
thread_title:  Aldosterone and American diets 

message: I'm a pharmacist in Canada, practicing for 7 years. Never have I ever called it spiro or heard anyone else refer to it as spiro. Maybe in the MTF transgender community this is a colloquialism, but within the professional setting and with our cardio patients it isn't a term used. (Usually I call it the peppermint pill if a patient can't remember the name! Best smell next to chewable carbamazepine and generic ranitidine.)  — Preceding unsigned comment added by 70.76.75.120 (talk) 01:04, 13 June 2013 (UTC)
thread_title:  Never heard of it being referred to as "Spiro" 

message: ===Hair loss===
Spironolactone can help to stop the hair from falling out and allow hair regrowth to occur (Rathnayake, 2010). This drug lowers androgen levels in the body. Androgens are hormones that both males and females have, although males have higher levels of them. It works by blocking androgen receptors and inhibiting ovarian androgen production (Rathnayake, 2010). Spironolactone competitively binds receptors at the aldosterone-dependent Na-K exchange site (Rathnayake, 2010). This binding leads to an increased excretion of sodium, chlorine, and water. It also leads to retention of potassium and hydrogen. Because Spironolactone inhibits these androgens they are not able to irritate the hair follicles and therefore hair loss can be halted. 
<ref“Alopecia areata.” American Academy of Dermatology. 2016.
Case-Lo, Christine. “Hair Loss and Testosterone.” Healthline. September 2013. 
Dinh, Q Quan and Sinclair, Rodney. “Female pattern hair loss: Current treatment concepts.” Clin Interv Aging. June 2, 2007. 2(2) 189-199. 
Rathnayake D, Sinclair R. “Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.” Dermatol Clin. July 2010. 28 (3) 611-618./ref> 
Doc James (talk · contribs · email) 22:31, 10 November 2016 (UTC)
thread_title: Needs proper formatting per [[WP:MEDHOW]]

message: Spironolactone can help to stop the hair from falling out and allow hair regrowth to occur (Rathnayake, 2010). This drug lowers androgen levels in the body. Androgens are hormones that both males and females have, although males have higher levels of them. It works by blocking androgen receptors and inhibiting ovarian androgen production (Rathnayake, 2010). Spironolactone competitively binds receptors at the aldosterone-dependent Na-K exchange site (Rathnayake, 2010). This binding leads to an increased excretion of sodium, chlorine, and water. It also leads to retention of potassium and hydrogen. Because Spironolactone inhibits these androgens they are not able to irritate the hair follicles and therefore hair loss can be halted. 
<ref“Alopecia areata.” American Academy of Dermatology. 2016.
Case-Lo, Christine. “Hair Loss and Testosterone.” Healthline. September 2013. 
Dinh, Q Quan and Sinclair, Rodney. “Female pattern hair loss: Current treatment concepts.” Clin Interv Aging. June 2, 2007. 2(2) 189-199. 
Rathnayake D, Sinclair R. “Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.” Dermatol Clin. July 2010. 28 (3) 611-618./ref> 
Doc James (talk · contribs · email) 22:31, 10 November 2016 (UTC)
thread_title: Hair loss

message: People can easily find these at pubmed. Plus t hey increase load times / page size. One or two would be fine but not twenty IMO. Doc James (talk · contribs · email) 23:13, 29 August 2018 (UTC)
thread_title: List of reviews

message: It is stated that in the "Metabolism" section: "The 7α-thiomethylated metabolites of spironolactone were not known for many years and it was originally thought that canrenone was the major active metabolite of the medication, but subsequent research identified 7α-TMS as the major metabolite."
The figures in "Pharmacodynamics" section also indicastes that "7α-Thiomethylspironolactone, the major active form of spironolactone." and "Canrenone, the second major active form of spironolactone."
In the "Absorption" section, however, it is "The relationship between a single dose of spironolactone and plasma levels of canrenone, a major active metabolite of spironolactone,..."
I don't have sufficient knowledge in this particular area, but I base on the abundant evidence among that text that 7α-Thiomethylspironolactone is the most major metabolite. Please resolve the statement in the "Absorption" section.
Hhthoj (talk) 14:16, 9 July 2019 (UTC)
thread_title:  Inconsistent major metabolites 

message: The two conditions are very similar. The main differentiating point is age - Barter affects children; Gitelman manifests in late puberty/adulthood.
Aside from that, many of the symptoms remain the same - defined largely by loss of potassium and magnesium in the urine, not caused by other medications or conditions, while other levels remain the same.
As an adult with Gitelman, I relied on Spironalactone for over a decade as it let me lead a normal life - until it was inexplibably taken off my prescription lists by a snafu from the nhs, which led to 43 hospital admissions - due to life-threatening hypokalemia - in just 48 months! Today, after a four year battle, i won the fight to be placed back on it due to the nhs having actually worsened my quality of life against the hippocratic oath.
So, I merely ask (due to their similarity), that a mention also be added alongside Barter's Syndrome that it is also used successfully to help people with Gitelman Syndrome to manage their condition due to its potassium-sparing properties. HeightConscious5 (talk) 23:17, 2 March 2020 (UTC)
thread_title:  Article mentions treatment of Barter's patients, but not Gitelman Syndrome patients. 

message: I believe you might be interested in adding this to the article: Mareev V.Yu., Orlova Y.A., Pavlikova E.P., Matskeplishvili S.T., Akopyan Z.A., Plisyk A.G., Seredenina E.M., Asratyan D.A., Potapenko A.V., Malakhov P.S., Samokhodskaya L.M., Mershina E.A., Sinitsyn V.E., Bulanova M.M., Fuks A.A., Mareev Yu.V., Begrambekova Yu.L., Kamalov A.A. Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)”. Kardiologiia. 2020;60(8):4-15. https://doi.org/10.18087/cardio.2020.8.n1307 (Direct link to PDF in English -- https://lib.ossn.ru/jour/article/viewFile/1307/862) -- Wesha (talk) 18:30, 5 June 2021 (UTC)
thread_title:  COVID treatment 

message: This graph is incredibly unfriendly to colorblind people and impossible to interpret. As a colorblind person, I'm not even certain that the lines for canrenone and 7a-thiomethylspironolactone are different colors but I can kind of imagine that they are. Any chance someone could adjust the colors so they're more distinct?  — Preceding unsigned comment added by 204.69.182.1 (talk) 17:30, 24 May 2022 (UTC)
thread_title:  Graph of spironolactone and metabolite levels 

message: Near as I can tell, there is no mention of this stuff's smell on this page. Can someone explain why Osyrol, listed as an artificial substitute on the sandalwood oil page, redirects here? 
The artificial sandalwood odorant is perhaps this osyrol - https://www.ventos.com/index.php/en/producto/4782/OSYROL - but I'm no expert on that either. 2600:8806:A413:B00:C1C9:B060:DF78:5214 (talk) 20:11, 4 March 2023 (UTC)
thread_title:  Osyrol redirect from sandalwood oil